Merck
CN
  • The prevalence of Helicobacter pylori gastritis in newly diagnosed children with inflammatory bowel disease.

The prevalence of Helicobacter pylori gastritis in newly diagnosed children with inflammatory bowel disease.

Helicobacter (2014-05-16)
Kleoniki Roka, Aikaterini Roubani, Kalliopi Stefanaki, Ioanna Panayotou, Eleftheria Roma, Giorgos Chouliaras
摘要

Recent studies have shown that patients with inflammatory bowel disease (IBD) are less likely to be infected with Helicobacter pylori compared with non-IBD patients. We aimed to study the prevalence of H. pylori-positive and H. pylori-negative gastritis in newly diagnosed children with IBD in comparison to those with non-IBD in Greece. All children who underwent first esophagogastroduodenal endoscopy between 2002 and 2011 were retrospectively included. Four groups were studied: patients with Crohn's disease (CD), ulcerative colitis (UC), IBD unclassified (IBDU), and non-IBD individuals (non-IBD). Helicobacter pylori infection was defined by positive culture or by positive histology and CLO test. Those children with negative or not available culture and only one positive test (histology or CLO) were further evaluated by urea breath test, and the positives were also included in the infected group. We studied 159 patients with IBD (66 CD, 34 UC, and 59 IBDU) and 1209 patients in non-IBD individuals. Helicobacter pylori gastritis was less frequent in the IBD group (3.8% vs 13.2% in the control group, p < .001), whereas IBD patients were significantly older than non-IBD children (p < .001). Children with H. pylori-negative gastritis were 3.3 times more likely to belong in the IBD group compared with H. pylori-positive patients (p = .006). Occurrence of H. pylori gastritis is less frequent in children with IBD compared with controls. Our study confirms an inverse association between H. pylori and IBD. Future studies are needed to distinguish between a true protective role of H. pylori and a confounding effect due to previous antibiotic use in children with IBD.

材料
货号
品牌
产品描述

Sigma-Aldrich
尿素, ACS reagent, 99.0-100.5%
Sigma-Aldrich
尿素, powder, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
尿素, ReagentPlus®, ≥99.5%, pellets
Supelco
尿素, 8 M (after reconstitution with 16 mL high purity water)
Sigma-Aldrich
尿素 溶液, BioUltra, ~8 M in H2O
Sigma-Aldrich
尿素, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%, 99.0-101.0% (calc. on dry substance)
Sigma-Aldrich
尿素, BioXtra, pH 7.5-9.5 (20 °C, 5 M in H2O)
Sigma-Aldrich
尿素, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99%
Sigma-Aldrich
尿素, suitable for electrophoresis
Sigma-Aldrich
尿素, BioUltra, for molecular biology, 99% (T)
USP
尿素, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
尿素 溶液, 40 % (w/v) in H2O
Sigma-Aldrich
尿素, meets USP testing specifications
Supelco
尿素, analytical standard
Millipore
尿素 溶液, suitable for microbiology, 40% in H2O
尿素, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
尿素-12C, 99.9 atom % 12C
Sigma-Aldrich
尿素, Vetec, reagent grade, 99%